Market Overview

UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data

Share:
Related BMRN
Why Leerink Adjusted Upside Expectations For 3 Biotechs
Biomarin Pharmaceutical Q4 Earnings Outlook
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results (Seeking Alpha)

Jefferies reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $44 to $46.

Jefferies said, "Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M."

BioMarin Pharmaceutical closed at $38.87 on Tuesday.

Latest Ratings for BMRN

DateFirmActionFromTo
Feb 2018Morgan StanleyMaintainsOverweightOverweight
Feb 2018Stifel NicolausMaintainsBuyBuy
Feb 2018Leerink SwannMaintainsOutperformOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!